CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

Charles River Laboratories International, Inc., founded in 1947 and headquartered in Wilmington, Massachusetts, is a leading non-clinical global drug development partner listed on the NYSE (CRL). The company supports pharmaceutical, biotechnology, academic, government, and industrial clients from early discovery through non-clinical development and manufacturing, aiming to make drug development more efficient, cost-effective, and faster. It operates through three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

RMS, its founding business, supplies research models—primarily purpose-bred rodents and select large models—along with related services such as Insourcing Solutions, Genetically Engineered Models and Services, Research Animal Diagnostic Services, and Cell Solutions; it generated 20.5% of 2024 revenue with about 4,100 employees. DSA, the largest segment at 60.5% of 2024 revenue and roughly 12,100 employees, provides discovery services (target identification through candidate selection) and regulated/non-regulated safety assessment (toxicology, pathology, safety pharmacology, bioanalysis, pharmacokinetics) supporting drugs, chemicals, vaccines, medical devices, and consumer products. Manufacturing Solutions, comprising Microbial Solutions (Endosafe, Celsis, Accugenix) and Biologics Solutions (Biologics Testing Services and a CDMO business for cell and gene therapies), accounted for 19.0% of 2024 revenue with about 2,800 employees, supporting quality control testing and advanced therapeutics manufacturing.

In 2024, total revenue was $4.0 billion, and the company operated over 130 sites in more than 20 countries. Facing a challenging demand environment, Charles River is undertaking a global footprint optimization initiative, expecting to close or consolidate about 15 additional sites over the next two years, primarily within DSA and RMS. The company also faces legal and regulatory scrutiny related to its non-human primate supply chain, including U.S. government investigations tied to a 2022 Department of Justice case involving a Cambodian NHP supplier, as well as related securities and derivative lawsuits.

Strategically, the company emphasizes its integrated early-stage research portfolio, comprehensive biopharmaceutical manufacturing capabilities, deep scientific expertise across therapeutic modalities, and commitment to animal welfare through its "3Rs" initiative (Replacement, Reduction, Refinement).